News
-
-
-
COMMUNIQUÉ DE PRESSE
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
NanoViricides, Inc. receives approval from CNES for Phase II clinical trial of NV-387 in DRC for MPox disease treatment. CEO highlights drug's broad-spectrum antiviral capabilities -
-
-
COMMUNIQUÉ DE PRESSE
Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It
NanoViricides, Inc. provides details on its Measles drug development program targeting the endemic potential of the virus in the USA and the effectiveness of their broad-spectrum antiviral drug NV-387 -
-
-
COMMUNIQUÉ DE PRESSE
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides, Inc. commences evaluation of clinical drug NV-387 for Measles virus treatment, utilizing innovative nanomedicine technology. Company aims to combat Measles outbreak and provide effective antiviral solution -
